Blog

December 16, 2020

How to Ensure Equitable Access to Cancer Treatment Selection During and Beyond COVID-19

Earlier this year, Canexia Health launched Project ACTT, Access to Cancer Testing & Treatment in Response to COVID-19, with support from the Canadian federal government via the Digital Technology Supercluster. Through ACTT, we are leading a consortium of partners to speed up cancer testing in Canada for targeted treatment selection during the pandemic through minimally invasive circulating tumor (ctDNA) testing.

Read More

Blog

November 13, 2020

Liquid Biopsy Offers New Hope for Ontario Family

COVID-19 has created serious challenges for people living with advanced-stage cancer. In response, Canexia Health launched Project ACTT this summer, a federally-funded program to provide liquid biopsy testing to 2,000 patients across Canada with advanced or metastatic breast, lung, and colorectal cancer. Here is one patient’s story.

Read More

Blog

November 9, 2020

4 Lessons for Late Stage Cancer Care During COVID-19

COVID-19 has had dramatic impacts on all aspects of healthcare, including treatment selection and monitoring of late stage cancers. Last week, Brady Davis, Canexia's SVP of Corporate Development, moderated a workshop on this topic as part of the Association for Molecular Pathology 2020 conference, bringing together four global experts in oncology and pathology.

Read More

Blog

September 22, 2020

Why Bring Liquid Biopsy Testing In-House? The Case for Millions in Cost Savings

We recently conducted a cost savings analysis for healthcare organizations interested in bringing liquid biopsy testing in-house. We discovered that, compared to outsourcing, in-house liquid biopsy testing with an actionable circulating tumor DNA (ctDNA) panel would enable healthcare organizations to attain substantial cost savings -- $2.7M per 1,000 cancer patients.

Read More

More Information at Your Fingertips

Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.

Learn More